Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ambea ABCHIX:AMBEAS 80 Revenue per Share is kr205.27 as of Jun. 2026. GuruFocus rates CHIX:AMBEAS with a GF Score™ of 80/100 and a GF Value™ of kr124.73 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 609 Healthcare Providers & Services companies, Ambea AB ranks better than 66.5% on this metric.
Ambea AB's revenue per share for the
three
months ended in Jun. 2026 was kr54.66.
Ambea AB's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was kr205.27.
Good Sign:
Ambea AB has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue Per Share Growth Rate of Ambea AB was 15.80% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 12.50% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 10.40% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 11.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Ambea AB's Revenue per Share or its related term are showing as below:
CHIX:AMBEAs'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 1.4 Med: 12.2 Max: 20.1
Current: 12.5
During the past 12 years, Ambea AB's highest 3-Year average Revenue Per Share Growth Rate was 20.10% per year. The lowest was 1.40% per year. And the median was 12.20% per year.
CHIX:AMBEAs's 3-Year Revenue Growth Rate is ranked better than 66.5% of 609
companies
in the Healthcare Providers & Services industry
Industry Median: 6.9
vs CHIX:AMBEAs: 12.50
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Ambea AB Revenue per Share Related Terms
Ambea AB Revenue per Share Historical Data
* Premium members only.
The historical data trend for Ambea AB's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:AMBEAS vs HCA, THC, EHC: Revenue per Share Comparison
For the Medical Care Facilities subindustry, Ambea AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ambea AB PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ambea AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Ambea AB's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Ambea AB's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr205.27
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ambea AB (CHIX:AMBEAS) has a Revenue per Share of kr205.27 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Ambea AB and its competitors. According to the industry distribution chart, Ambea AB ranks #204 out of 609 companies in the Healthcare Providers & Services industry, placing it in the top 33.5%.
Is Ambea AB's Revenue per Share too high?
Ambea AB's current Revenue per Share is kr205.27. Based on the distribution chart, Ambea AB ranks #204 out of 609 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Ambea AB has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ambea AB's Revenue per Share compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Ambea AB ranks #204 out of 609 companies for Revenue per Share. This puts Ambea AB in the upper half of its industry. The industry median Revenue per Share is 6.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Healthcare Providers & Services company?
The median Revenue per Share among Healthcare Providers & Services companies is 6.90, based on 609 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Ambea AB and its competitors. For the Healthcare Providers & Services industry, the median Revenue per Share is 6.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ambea AB's current Revenue per Share is kr205.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambea AB stock overvalued right now?
Based on GuruFocus' analysis, Ambea AB (CHIX:AMBEAS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr124.73, compared to a current price of kr144.20 — trading 15.6% above its estimated fair value. The current Revenue per Share is kr205.27. Ambea AB's overall GF Score™ is 80/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Ambea AB (CHIX:AMBEAS), the current Revenue per Share is kr205.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ambea AB (CHIX:AMBEAS) Overvalued in 2026?
Based on GuruFocus' analysis, Ambea AB stock appears to be overvalued.
The current stock price of kr144.20 is trading 15.6% above its estimated GF Value™ of kr124.73.
GuruFocus considers Ambea AB to be Modestly Overvalued.
Key valuation signals for CHIX:AMBEAS:
Revenue per Share: kr205.27
GF Value™: kr124.73 vs. price of kr144.20 (15.6% above fair value)
No single metric tells the full story. See the CHIX:AMBEAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ambea AB is a Swedish care-provider group focused on elderly care, disability care, psychosocial support, housing, staffing, and training across the Nordic region. The company's segment includes: i) Nytida: Comprises social care services for children, youth and adults, in Sweden, ii) Vardaga: Comprises nursing homes and home care in Sweden, iii) Stendi: Comprises social care for children, youth and adult in Norway, iv) Validia: Comprises social care for children, v) Altiden: Comprises social care for children, youth and adults as well as elderly care in Denmark, and vi) Klara: Comprises competence and staffing solutions for elderly and social care, and student health services in Sweden. The majority of the company's revenue is derived from the Vardaga segment.
80GF Score
Get the complete analysis for CHIX:AMBEAS
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMBEAS has been successfully added to your 
